DCAL · NSE
Dishman Carbogen Amcis Limited
₹170.52
+5.19% (+₹8.41)
Prev. close
₹162.11
Volume
7,27,114
Delivery %
39.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes; ammonium and phosphonium; quats, phosphoranes, and wittig reagents; generic intermediates; cholesterol and lanolin-related products; sterile injectables; specialty chemicals and disinfectants, as well as hand and body wash, sanitizers, and antiseptic formulations. It also provides encapsulation and formulation capabilities; phase transfer catalysts; drug product, finished, and HiPo formulations; generic and highpotent APIs; Health and personal care solutions; and drug linkers and payloads. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Himani S. Dhotre
Headquarters
Ahmedabad
Employees
934
Website
imdcal.comExchange
View on NSE ↗Key stats
Market cap
₹2,673.47 Cr
P/E ratio (TTM)
27.4
EPS (TTM)
₹6.23
Beta (1Y · daily vs NIFTY 50)
1.84
Beta (5Y · monthly vs NIFTY 50)
1.58
Shares float
5.52 Cr
EPS · quarter ended Mar 2026
₹1.39
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 4.2% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,912.03 Cr | ₹2,140.69 Cr | ₹2,412.92 Cr | ₹2,615.77 Cr | ₹2,711.50 Cr | ₹2,931.90 Cr | |
| EBITDA | ₹290.52 Cr | ₹360.15 Cr | ₹300.52 Cr | ₹308.57 Cr | ₹472.51 Cr | ₹597.46 Cr |
| ₹-165.13 Cr | ₹18.01 Cr | ₹-29.80 Cr | ₹-153.45 Cr | ₹3.24 Cr | ₹97.45 Cr | |
| Diluted EPS | ₹-10.53 | ₹1.15 | ₹-1.9 | ₹-9.79 | ₹0.21 | ₹6.22 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹8,356.00 Cr | ₹8,634.00 Cr | ₹9,439.00 Cr | ₹9,571.00 Cr | ₹9,987.00 Cr | ₹11,923.00 Cr | |
| — | ₹1,829.89 Cr | ₹2,208.85 Cr | ₹2,312.60 Cr | ₹2,388.95 Cr | ₹3,076.06 Cr | |
| Stockholders' equity | ₹5,698.00 Cr | ₹5,549.00 Cr | ₹5,809.00 Cr | ₹5,627.00 Cr | ₹5,831.00 Cr | ₹6,677.00 Cr |
Current assets, Trade receivables, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹513.00 Cr | ₹355.00 Cr | ₹266.00 Cr | ₹379.00 Cr | ₹375.00 Cr | ₹491.00 Cr | |
| Investing cash flow | ₹-380.79 Cr | ₹-618.53 Cr | ₹-494.08 Cr | ₹-229.52 Cr | ₹-192.21 Cr | ₹-245.34 Cr |
| ₹-11.00 Cr | ₹130.00 Cr | ₹250.00 Cr | ₹-22.00 Cr | ₹-102.00 Cr | ₹201.00 Cr | |
| Capital expenditure | ₹-366.03 Cr | ₹-463.80 Cr | ₹-619.68 Cr | ₹-303.25 Cr | ₹-216.76 Cr | ₹-265.98 Cr |
| End cash position | ₹243.54 Cr | ₹110.24 Cr | ₹131.79 Cr | ₹264.09 Cr | ₹341.07 Cr | ₹787.76 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 59.32% |
| Public | 40.68% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Dishman Carbogen Amcis Limited | ₹2,541.61 Cr | ₹162.11 | 26.1 | 0.38 | 1.5% | 0.46 | +8.9% | -41.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
7 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Dishman Carbogen Amcis shares jump over 5% after Swiss subsidiary clears US FDA inspection with zero observations
Dishman Carbogen Amcis shares rose over 5% after its Swiss subsidiary, CARBOGEN AMCIS AG, successfully completed a US FDA inspection with zero observations. This marks a significant regulatory milestone for the company, especially after reporting a net loss in Q1 FY27. The clean inspection at its Vionnaz facility is a positive development for the company.